Verrica, itself or through its Affiliates, Sublicensees, or Subcontractors, shall use Commercially Reasonable Efforts, at its sole cost and expense, to Develop the Product in the Licensed Field in the Territory, including to achieve the development milestone events by certain target dates contained in the Development Plan. Verrica shall, and Verrica shall cause its Affiliates, Sublicensees and its Subcontractors to, conduct all Development under this Agreement in a professional manner and in compliance with all Applicable Laws, including applicable GLP, cGMP and GCP.

Development Diligence. Alexion shall use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least ​. Alexion will have no other diligence obligations under this Agreement with respect to the Development of Licensed Products.

Development Diligence. Lian (directly, or through their respective Affiliates, Sublicensees and contractors) will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for the Licensed Product in the Territory, and Lyra (directly, or through its respective Affiliates, Sublicensees and contractors) will use Commercially Reasonable Efforts to # complete the planned Global Phase III Trial for the Licensed Product (subject to Lian’s compliance with its diligence obligations in this Section 3.1(a) (Development Diligence) with respect to such Global Phase III Trial), and # seek and obtain Regulatory Approval for the Licensed Product in the U.S. Without limiting the foregoing and subject to Lyra’s compliance with its diligence obligations in the foregoing sub-clauses (i) and (ii) (but not, for clarity, dependent upon the prior completion of the activities in the foregoing sub-clauses (i) and (ii)), Lian will ​ engage Clinical Trial sites in the Territory and enroll up to ​ of the total number of Clinical Trial subjects in the planned Global Phase III Trial for the Licensed Product to be conducted by Lyra and Lian; provided that, ​.

Development Diligence. Ji Xing shall carry out the initial Development Plan and subsequent Development Plans approved by the JDC and shall otherwise use Diligent Efforts to Develop the Product ​. Without limiting the foregoing, Ji Xing shall use Diligent Efforts to ​.

Lilly shall use Commercially Reasonable Efforts during the Term to Develop, either itself or through one or more Lilly Affiliates or Sublicensees, ​ and shall commit such resources (including employees, agents, consultants, facilities, equipment and materials) as are necessary to comply with such diligence obligation.

Development Diligence. Kite shall (either directly or through one or more Affiliates or Sublicensees) use Commercially Reasonable Efforts ​.

Development Efforts; Diligence. Neurocrine shall use Neurocrine’s Commercially Reasonable Efforts to conduct all Development activities under the Neurocrine Development Plans. Neurocrine shall conduct such activities in accordance with the timelines in the Neurocrine Development Plans, in good scientific manner and in compliance with all applicable Laws. Neurocrine shall be solely responsible for all Subsequent Development; provided that Neurocrine shall use Neurocrine’s Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least two (2) Products in the Field in the Major Markets. Without limiting the foregoing, following IND Acceptance of an IND for [[Unknown Identifier]] in SCN8A-EE, Neurocrine shall use Neurocrine’s Commercially Reasonable Efforts to complete a Phase 2 Clinical Trial of a [[Unknown Identifier]] Product in [[Unknown Identifier]].

Development Diligence. Ji Xing shall carry out the initial Development Plan and subsequent Development Plans approved by the JDC and shall otherwise use Diligent Efforts to Develop the Product ​. Without limiting the foregoing, Ji Xing shall use Diligent Efforts to ​.

Development Diligence. Each Party will use Commercially Reasonable Efforts to perform the obligations assigned to it under the Global Development Plan. GSK (directly, or through its Affiliates, its or their Sublicensees and subcontractors) will use Commercially Reasonable Efforts to Develop the Licensed Products in the Field in the Territory, including to obtain and maintain Regulatory Approval of Licensed Products in the Field in the United Kingdom, Germany, Italy, France, Spain, China, Japan, and, in the event that ITEOS has delivered an Opt-Out Notice, the United States.

Development Diligence Obligations. [[FibroGen:Organization]] will use Commercially Reasonable Efforts to Develop in accordance with the Development Plan, and obtain and maintain Regulatory Approval for, ​ Licensed Product Directed To each Licensed Program in the Field in ​ Major Market Countries. [[FibroGen:Organization]] shall use Commercially Reasonable Efforts to ​ (each of the events as provided in the [foregoing (i) through (iii)] are a “Diligence Milestone”). If [[FibroGen:Organization]] makes a final decision to permanently cease Development of all Licensed Products for a Licensed Program, [[FibroGen:Organization]] shall give HFB written notice within ​ of such decision and such Licensed Program shall be a Terminated Licensed Program pursuant to [Section 13.6] (Effects of Termination).